{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:11:25Z","timestamp":1794085885175,"version":"4.8.0"},"reference-count":47,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"laboratory Basilea Pharmaceutica International Ltd., Allschwil, Hegenheimermattweg 167b, Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: To compare the real-life effectiveness and safety of ceftaroline fosamil (ceftaroline-F) and ceftobiprole medocaril (ceftobiprole-M) for infections in hospitalized patients. Methods: This comparative, observational, retrospective, and multicenter Spanish study included patients receiving outpatient parenteral antimicrobial therapy (OPAT) and hospitalized patients treated for at least 48 h with ceftaroline-F or ceftobiprole-M between their first incorporation in the clinical protocol of each hospital and 31 July 2022. Results: Ceftaroline-F was administered to 227 patients and ceftobiprole-M to 212. In comparison to the latter, ceftaroline-F-treated participants were younger (63.02 vs. 66.40 years, OR 1.1; 95%CI: 1.001\u20131.05) and had higher rates of septic shock (OR 0.27; 95%CI: 0.09\u20130.81) and higher frequencies of targeted (57.7 vs. 29.7%; OR: 0.35; 95%CI: 0.18\u20130.69) and combined (89.0 vs. 45.8%, OR: 0.13; 95%CI: 0.06\u20130.28) therapies that were second line or more (82.4% vs. 64.6%%; OR 0.35; 95%CI: 0.18\u20130.69), and higher rates of infections due to Gram-positive cocci (92.7 vs. 64.7%, p = 0.001), bacteremia (51.9 vs. 21.7%, p = 0.001), infective endocarditis (24.2 vs. 2.4%, p = 0.0001), and mechanical ventilation-associated pneumonia (8.8 vs. 2.4%, p = 0.0001). Ceftobiprole-M was more frequently administered against polymicrobial infections (38.1 vs. 14.0%, p = 0.001), those produced by Gram-negative bacilli (19.7 vs. 6.0%, p = 0.0001), nosocomial pneumonia (33 vs. 10.6%, p = 0.0001), and skin and soft-tissue infections (25.4 vs. 10.1%, p = 0.0001). Patients treated with ceftaroline-F had a longer hospital stay (36 (IQR: 19\u201360) vs. 19.50 (IQR: 12\u201330.75, p = 0.0001) days), with no difference in infection-related mortality at 14 (13.2 vs. 8.0%, p = 0.078) or 28 (4.8 vs. 3.3%, p = 0.415) days or in dropout rate for adverse effects (2.2 vs. 0.9%; p = 1). Conclusions: The fifth-generation cephalosporins, ceftaroline-F and ceftobiprole-M, are safe and effective in real life, with no difference between them in health outcomes.<\/jats:p>","DOI":"10.3390\/antibiotics12121692","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T13:45:41Z","timestamp":1701524741000},"page":"1692","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ceft-to-Ceft Study: Real-Life Experience with Ceftaroline and Ceftobiprole in Treatment of the Principal Infectious Syndromes in a Spanish Multicenter Hospital Cohort"],"prefix":"10.3390","volume":"12","author":[{"given":"Daniel","family":"Arn\u00e9s Garc\u00eda","sequence":"first","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Pitto-Robles","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Calder\u00f3n Parra","sequence":"additional","affiliation":[{"name":"Unidad Enfermedades Infecciosas, Hospital Puerta de Hierro de Majadahonda, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Calvo Salvador","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Puerta de Hierro de Majadahonda, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Herrero Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas y Microbiolog\u00eda, Complejo Hospitalario de Ja\u00e9n, 23007 Ja\u00e9n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Hospital Universitario M\u00fatua de Terrassa, 08221 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-5728","authenticated-orcid":false,"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de las Nieves, Instituto de Investigaci\u00f3n Biosanitario de Granada (IBS-Granada), 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","unstructured":"ECDC (2023, August 06). Antimicrobial Resistance Surveillance in Europe, 2022\u20132020 Data. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-surveillance-europe-2022-2020-data."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE Surveillance Program (2008\u20132010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jmii.2020.04.017","article-title":"In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012\u20132018","volume":"54","author":"Jean","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jac\/dkr095","article-title":"Ceftaroline fosamil: A new broad-spectrum cephalosporin","volume":"66","author":"Laudano","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/jac\/dkv415","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: Individual patient data meta-analysis of randomized controlled trials","volume":"71","author":"Taboada","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: The first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections on behalf of the CANVAS 1 investigators","volume":"65","author":"Corey","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/jac\/dkw326","article-title":"Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: A matched cohort study","volume":"71","author":"Athans","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijantimicag.2019.06.025","article-title":"Off-label use of ceftaroline fosamil: A systematic review","volume":"54","author":"Pani","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.37201\/req\/s01.09.2021","article-title":"Ceftobiprole: A clinical view","volume":"34","year":"2021","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lupia, T., Pallotto, C., Corcione, S., Boglione, L., and De Rosa, F.G. (2021). Ceftobiprole Perspective: Current and Potential Future Indications. Antibiotics, 10.","DOI":"10.3390\/antibiotics10020170"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.diagmicrobio.2007.02.010","article-title":"In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection","volume":"58","author":"Rouse","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijantimicag.2013.09.013","article-title":"Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays","volume":"43","author":"Abbanat","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole Compared with Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jval.2017.08.3019","article-title":"Good Practices for Real-World Data Studies of Treatment and\/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making","volume":"20","author":"Berger","year":"2017","journal-title":"Value Health"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e02483-18","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/jac\/dku236","article-title":"Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes","volume":"69","author":"Barber","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13054-020-02950-2","article-title":"Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019\u2014Results from a systematic review and meta-analysis","volume":"24","author":"Bauer","year":"2020","journal-title":"Crit. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1179\/1973947814Y.0000000184","article-title":"Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience","volume":"26","author":"Ramani","year":"2014","journal-title":"J. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/21548331.2015.1037228","article-title":"Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"43","author":"Kaye","year":"2015","journal-title":"Hosp. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","article-title":"Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience","volume":"53","author":"Destache","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.recesp.2019.09.023","article-title":"Mortalidad a corto y largo plazo de pacientes con indicaci\u00f3n quir\u00fargica no intervenidos en el curso de la endocarditis infecciosa izquierda","volume":"73","author":"Cediel","year":"2020","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14787210.2021.1927711","article-title":"Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial skin and skin structure infection: A systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Lan","year":"2022","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_30","unstructured":"Zevtera (Ceftobiprole) (2021). Product Monograph, AVIR Pharma Inc.. Available online: https:\/\/www.avirpharma.com\/pdf\/Product-Monograph-Zevtera.pdf."},{"key":"ref_31","first-page":"104790","article-title":"Real-life use of ceftobiprole for severe infections in a French intensive care unit","volume":"27","author":"Bellut","year":"2023","journal-title":"Infect. Dis. Now"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Musuuza, J.S., Watson, L., Parmasad, V., Putman-Buehler, N., Christensen, L., and Safdar, N. (2021). Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251170"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jcrc.2009.09.001","article-title":"The effect of comorbidity and age on hospital mortality and length of stay in patients with sepsis","volume":"25","author":"Yang","year":"2010","journal-title":"J. Crit. Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11739-021-02847-0","article-title":"Prognostic factors for late death in septic shock survivors: A multi-center, prospective, registry-based observational study","volume":"17","author":"Kim","year":"2022","journal-title":"Intern. Emerg. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio, C., G\u00e1lvez, J., Mart\u00ednez-Marcos, F.J., Plata-Ciezar, A., De La Torre-Lima, J., L\u00f3pez-Cort\u00e9s, L.E., Noureddine, M., Reguera, J.M., Vinuesa, D., and Garc\u00eda, M.V. (2020). Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-4895-1"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1465-9921-15-6","article-title":"Early versus later response to treatment in patients with community-acquired pneumonia: Analysis of the REACH study","volume":"15","author":"Blasi","year":"2014","journal-title":"Respir. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2165\/11635660-000000000-00000","article-title":"Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections","volume":"72","author":"Lodise","year":"2012","journal-title":"Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jgar.2020.03.010","article-title":"Real-life experience with ceftobiprole in a tertiary-care hospital","volume":"22","author":"Andini","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jgar.2021.01.014","article-title":"Real-life experience with ceftobiprole in Canada: Results from the CLEAR (Canadian Leadership on Antimicrobial Real-life usage) registry","volume":"24","author":"Zhanel","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ofid\/ofz168","article-title":"Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes","volume":"6","author":"Sullivan","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"106883","DOI":"10.1016\/j.ijantimicag.2023.106883","article-title":"Clinical results with the use of ceftaroline and ceftobiprole: Real-life experience in a tertiary care hospital","volume":"62","author":"Zampino","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jclinepi.2008.01.006","article-title":"The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients","volume":"61","author":"Charlson","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/313753","article-title":"Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis","volume":"30","author":"Li","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2023). Breakpoint Tables for Interpretation of MICs and Zone Diameters, European Committee on Antimicrobial Susceptibility Testing. Version 13.0."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","article-title":"Sepsis and septic shock","volume":"392","author":"Cecconi","year":"2018","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.chest.2020.05.598","article-title":"Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies","volume":"158","author":"Ramirez","year":"2020","journal-title":"Chest"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0213-005X(07)74242-8","article-title":"Gu\u00eda para el diagn\u00f3stico y tratamiento del paciente con bacteriemia. Gu\u00edas de la Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC)","volume":"25","year":"2007","journal-title":"Enferm. Infecc. Microbiol. Clin."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/12\/1692\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:36:42Z","timestamp":1760132202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/12\/1692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["antibiotics12121692"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12121692","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,2]]}}}